Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Marrying immunotherapy with chemotherapy: why say IDO?

Literature DB >> 16166276

Marrying immunotherapy with chemotherapy: why say IDO?

Alexander J Muller¹, George C Prendergast.

Abstract

Activation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) in cancer cells facilitates immune escape. A recent study now shows how small-molecule inhibitors of IDO can be used to leverage the efficacy of traditional chemotherapeutic drugs that are used to treat cancer in the clinic. By promoting antitumor immune responses in combination with cytotoxic chemotherapy, IDO inhibitors may offer a drug-based strategy to more effectively attack systemic cancer.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2005 PMID： 16166276 DOI： 10.1158/0008-5472.CAN-05-2213

Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701

Keyword Cloud
Cited

32 in total

Review 1. Structure and function of cationic amino acid transporters (CATs).

Authors: E I Closs; J-P Boissel; A Habermeier; A Rotmann
Journal: J Membr Biol Date: 2007-04-06 Impact factor: 1.843

2. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

Authors: Hilko Ardon; Stefaan Van Gool; Isabel Spencer Lopes; Wim Maes; Raf Sciot; Guido Wilms; Philippe Demaerel; Patricia Bijttebier; Laurence Claes; Jan Goffin; Frank Van Calenbergh; Steven De Vleeschouwer
Journal: J Neurooncol Date: 2010-02-10 Impact factor: 4.130

3. O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Authors: William P Malachowski; Maria Winters; James B DuHadaway; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Maisha Rahman; Eesha Sheikh; Judith M LaLonde; Syun-Ru Yeh; George C Prendergast; Alexander J Muller
Journal: Eur J Med Chem Date: 2015-12-17 Impact factor: 6.514

4. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase.

Authors: Mee Young Chang; Courtney Smith; James B DuHadaway; Jennifer R Pyle; Janette Boulden; Alejandro Peralta Soler; Alexander J Muller; Lisa D Laury-Kleintop; George C Prendergast
Journal: Cancer Biol Ther Date: 2011-12-15 Impact factor: 4.742

10. Dendritic Cells Treated with Exogenous Indoleamine 2,3-Dioxygenase Maintain an Immature Phenotype and Suppress Antigen-specific T cell Proliferation.

Authors: Evelyn Bracho-Sanchez; Azadeh Hassanzadeh; Maigan A Brusko; Mark A Wallet; Benjamin G Keselowsky
Journal: J Immunol Regen Med Date: 2019-02-10

Marrying immunotherapy with chemotherapy: why say IDO?

Review 1. Structure and function of cationic amino acid transporters (CATs).

2. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

3. O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

4. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase.

Review 5. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

6. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Review 7. IDO expression in the brain: a double-edged sword.

Review 8. BAR the door: cancer suppression by amphiphysin-like genes.

9. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target.

10. Dendritic Cells Treated with Exogenous Indoleamine 2,3-Dioxygenase Maintain an Immature Phenotype and Suppress Antigen-specific T cell Proliferation.